Back to today’s briefing

Story perspectives

HK Innovation's K-CAB Outshines Lansoprazole in U.S. Trials

4/24/2025

45 5

Summary

Story summary

HK inno. N's K tegoprazan (K-CAB) has made waves in U.S. phase 3 trials, surpassing lansoprazole for acid reflux treatment. It not only excelled in healing erosive esophagitis but also provided complete symptom relief for non-erosive reflux disease. With over 2,000 patients involved, an FDA filing is anticipated later this year, promising hope for many.

1 of 1

Story summary

HK inno. N's K tegoprazan (K-CAB) has made waves in U.S. phase 3 trials, surpassing lansoprazole for acid reflux treatment. It not only excelled in healing erosive esophagitis but also provided complete symptom relief for non-erosive reflux disease. With over 2,000 patients involved, an FDA filing is anticipated later this year, promising hope for many.